Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC daily Stock Chart
AstraZeneca PLC
Index- P/E42.36 EPS (ttm)0.97 Insider Own0.50% Shs Outstand2.53B Perf Week10.56%
Market Cap103.69B Forward P/E24.89 EPS next Y1.64 Insider Trans0.00% Shs Float2.52B Perf Month14.33%
Income2.45B PEG3.21 EPS next Q0.76 Inst Own18.40% Short Float0.49% Perf Quarter-1.37%
Sales21.45B P/S4.83 EPS this Y-13.40% Inst Trans0.62% Short Ratio2.46 Perf Half Y6.42%
Book/sh4.71 P/B8.69 EPS next Y-1.20% ROA3.90% Target Price41.88 Perf Year18.82%
Cash/sh1.67 P/C24.52 EPS next 5Y13.20% ROE18.50% 52W Range32.69 - 41.78 Perf YTD7.74%
Dividend1.40 P/FCF- EPS past 5Y-13.50% ROI13.30% 52W High-2.05% Beta0.46
Dividend %3.42% Quick Ratio0.70 Sales past 5Y-4.30% Gross Margin79.50% 52W Low25.18% ATR0.81
Employees61100 Current Ratio0.90 Sales Q/Q-14.30% Oper. Margin14.00% RSI (14)72.63 Volatility1.76% 1.30%
OptionableYes Debt/Eq1.75 EPS Q/Q-37.20% Profit Margin11.30% Rel Volume1.28 Prev Close39.98
ShortableYes LT Debt/Eq1.54 EarningsFeb 14 BMO Payout141.60% Avg Volume4.99M Price40.92
Recom1.60 SMA2011.71% SMA509.19% SMA2008.52% Volume6,379,784 Change2.35%
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Apr-05-17Downgrade UBS Buy → Neutral
Feb-15-19 08:42AM  Strength Seen in AstraZeneca (AZN): Stock Soars 9.3% Zacks
Feb-14-19 04:26PM  Why Marathon Oil, AstraZeneca, and Bloomin' Brands Jumped Today Motley Fool +9.29%
04:12PM  AstraZeneca Earnings Beat Views; Company Says It's 'Returned To Growth' Investor's Business Daily
12:45PM  FTSE 100 squeezes out gains; ConvaTec drags midcaps Reuters
12:30PM  AstraZeneca Earnings: AZN Stock Zooms Higher on Q4 Beat InvestorPlace
12:21PM  European shares give up three-month highs after shock U.S. data Reuters
12:19PM  European shares give up 3-month highs after shock U.S. data Reuters
11:13AM  AstraZeneca Earnings Beat Views; Company Says It's 'Returned To Growth' Investor's Business Daily
11:12AM  AstraZeneca retires MedImmune brand; Jallal leaves for new company American City Business Journals
10:02AM  Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise Zacks
09:30AM  BMY vs. AZN: Which Stock Is the Better Value Option? Zacks
09:00AM  Tanabe Research Labs Announce FDA Acceptance of its IND Application for TR1801-ADC (MT-8633), an ADC Targeting cMet Positive Solid Tumors PR Newswire
08:58AM  AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales Zacks
08:28AM  [$$] AstraZeneca Turns a Corner After a Decade of Struggles The Wall Street Journal
07:24AM  Brexit preparations have cost £40 million to £50 million: AstraZeneca CEO CNBC Videos
07:23AM  New cancer drugs, China give AstraZeneca welcome sales boost Reuters
05:30AM  Astrazeneca: 4Q Earnings Snapshot Associated Press
05:04AM  AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook
03:44AM  European shares hit 3-month highs as Nestle, Airbus, AstraZeneca shine Reuters
03:33AM  [$$] AstraZeneca Sales Rise The Wall Street Journal
02:41AM  [$$] New drugs help AstraZeneca sales rebound Financial Times
Feb-13-19 05:17PM  Why Ironwood's Shares Climbed 11.7% on Wednesday Motley Fool
Feb-11-19 08:02AM  Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study GlobeNewswire
Feb-08-19 07:51AM  Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs Zacks
Feb-06-19 12:16PM  Congress invites 7 drugmakers to testify at potentially hostile hearing on drug prices. Here's what they're saying CNBC
Feb-05-19 04:06PM  Merck CEO Frazier to testify at Senate drug pricing hearing Reuters
11:38AM  Pharma execs will testify before Congress 'one way or another,' US senator says CNBC
09:45AM  AstraZeneca's infant respiratory drug prioritised in Europe, U.S. Reuters
Feb-04-19 10:10AM  Why Astrazeneca (AZN) Could Beat Earnings Estimates Again Zacks
09:27AM  Alkermes Sinks as FDA Refuses to Approve Depression Drug Zacks
Feb-01-19 11:00AM  Merck Pops On Quarterly Beat As Keytruda Sales Jump Despite U.S. Lag Investor's Business Daily
09:49AM  Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines Zacks
Jan-29-19 11:07AM  New life science internship program launches to help boost diversity American City Business Journals
Jan-28-19 05:26PM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks
04:14PM  Why UPMC Health Plan reached Brilinta deal with big pharmaceutical company American City Business Journals
11:00AM  AstraZeneca, UPMC Health Plan sign risk-sharing deal for heart medicine American City Business Journals
09:55AM  Merck (MRK) Q4 Earnings Coming Up: What's in the Cards? Zacks
07:02AM  Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe Zacks
05:15AM  Wallenberg Family Fortune Feels the Sting of Brexit, Trump Bloomberg
Jan-24-19 01:00PM  What's Behind the Biotech ETF Rally to Start 2019? Zacks
08:00AM  Today's Research Reports on Trending Tickers: Teva Pharmaceutical Industries and AstraZeneca ACCESSWIRE
Jan-23-19 07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-18-19 09:11AM  Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY Zacks
06:41AM  Immunomedics Gets CRL From FDA for Breast Cancer Candidate Zacks
Jan-17-19 09:30AM  NVS or AZN: Which Is the Better Value Stock Right Now? Zacks
Jan-16-19 10:05AM  Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C Zacks
06:25AM  BRIEF-Luye Pharma Reaches Strategic Partnership With Astrazeneca, Strengthens Commitment To Cardiovascular Therapeutic Field Reuters
Jan-15-19 07:14PM  BRIEF-Luye Pharma Announces Grant Of Promotion Right Of Xuezhikang Capsules In China To Astrazeneca Reuters
Jan-14-19 05:52PM  Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe Investor's Business Daily
12:09PM  House Democrats launch drug-pricing probe into a dozen major health-care companies CNBC
11:57AM  Sell Amarin Stock on the Recent Takeover Rumors Rally InvestorPlace
10:22AM  Can Inovio Pharmaceuticals Stock Keep Bounding Higher? Motley Fool
08:39AM  What's in Store for Merck in 2019 After a Solid Run in '18? Zacks
04:24AM  AstraZeneca Departures Continue as Medical Chief Bohen Exits Bloomberg
Jan-10-19 04:38PM  Astrazeneca lays off 210 as it closes drug manufacturing plants in Boulder, Longmont American City Business Journals
05:00AM  Top Picks 2019- AstraZeneca PLC AZN MoneyShow
Jan-09-19 07:02PM  MoCo economic development officials plan satellite office in Boston American City Business Journals
10:04AM  Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks
Jan-07-19 08:14PM  [$$] AstraZeneca Appoints Controversial Cancer Doctor to Head Research Unit The Wall Street Journal
02:28PM  AstraZeneca hires former Sloan Kettering specialist to lead oncology R&D unit American City Business Journals
10:34AM  AstraZeneca picks Baselga to lead oncology R&D in growth plan Reuters
09:50AM  Ironwood to Get New CEO, Current CEO to Head Latest Spinoff Zacks
09:31AM  AstraZeneca picks Baselga to lead oncology R&D in growth plan Reuters
09:28AM  [$$] AstraZeneca Appoints Controversial Cancer Doctor to Head Research Unit The Wall Street Journal
09:27AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
08:30AM  AstraZeneca appoints Baselga to head R&D for oncology Reuters
02:07AM  Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2 PR Newswire
Jan-06-19 10:50PM  [$$] AstraZeneca hires controversial head of cancer R&D Financial Times
Jan-04-19 07:08PM  Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO The Wall Street Journal
12:29PM  Ironwood co-founder, CEO will step down to head new spinout American City Business Journals
11:01AM  Ironwood Pharmaceuticals Picks AstraZeneca Executive to Be Next CEO The Wall Street Journal
10:07AM  Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate Zacks
Jan-03-19 10:10AM  Why the Earnings Surprise Streak Could Continue for Astrazeneca (AZN) Zacks
Jan-02-19 04:27PM  Could This New Biotech IPO Could Score Big With A Cancer Vaccine? Investor's Business Daily
09:35AM  U.K. Manufacturers Step Up Stockpiling as Brexit Looms Bloomberg
Jan-01-19 06:22AM  What Should You Know About The Future Of AstraZeneca PLCs (LON:AZN)? Simply Wall St.
Dec-30-18 03:27PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Dec-27-18 06:06PM  Immunomedics Enters Into Supply Deal for Breast Cancer Drug Zacks
08:20AM  Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019 Zacks
Dec-24-18 09:53AM  Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more American City Business Journals
08:07AM  The Zacks Analyst Blog Highlights: Procter & Gamble, Oracle, United Parcel Service, FedEx and AstraZeneca Zacks
Dec-21-18 01:36PM  Top Research Reports for Procter & Gamble, Oracle & United Parcel Service Zacks
09:13AM  Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations Zacks
Dec-20-18 05:34PM  AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting Zacks
04:14PM  Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes Investor's Business Daily
02:24PM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
09:09AM  AstraZeneca stock up 2.8% after announcing EU approval of COPD treatment MarketWatch
08:38AM  Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base Zacks
07:00AM  Phase III OLYMPUS and ROCKIES Trials for roxadustat Met Their Primary Endpoints in Chronic Kidney Disease Patients With Anemia Business Wire
03:02AM  AstraZeneca's ovarian cancer and anaemia treatments meet goals in late-stage studies Reuters
02:57AM  AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies Reuters
02:52AM  [$$] Pharma Giants Plan Drug Price Hike: Report The Wall Street Journal
Dec-19-18 07:48PM  Exclusive: Big Pharma returning to U.S. price hikes in January after pause Reuters
04:38PM  AstraZeneca's ovarian cancer drug gets FDA nod as maintenance treatment Reuters
04:01PM  LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer Business Wire
Dec-18-18 08:21PM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
05:18PM  Why a kidney disease drug approval in China is just the start for this S.F. company American City Business Journals
09:30AM  BMY vs. AZN: Which Stock Should Value Investors Buy Now? Zacks
06:24AM  China first to approve AstraZeneca, FibroGen anaemia drug Reuters
Dec-17-18 03:22PM  Merck to Acquire Europe's Antelliq Group for $2.4 Billion Zacks
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerOct 22Buy5.00600,0003,000,0003,004,554Oct 24 04:16 PM
ASTRAZENECA PLC10% OwnerSep 28Buy15.00246,6663,699,9902,164,855Oct 02 09:35 PM